SEC Form 4 · accession 0001179110-18-008564
Celldex Therapeutics, Inc. · CLDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Tibor Keler
Officer — Executive VP & CSO
Period of report
Jun 13, 2018
Accepted (ET)
Jun 15, 2018 · 7:42 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000744218
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Option (right to buy)F1,F2 | $0.6011 | Jun 13, 2018 | A | 390,000 | A | Jun 13, 2019 | Jun 13, 2028 | Common Stock | 390,000 | 390,000 | D |
Explanation of responses
- F1Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan.
- F225% vest on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.